全文获取类型
收费全文 | 9945篇 |
免费 | 621篇 |
国内免费 | 72篇 |
专业分类
耳鼻咽喉 | 41篇 |
儿科学 | 155篇 |
妇产科学 | 126篇 |
基础医学 | 1235篇 |
口腔科学 | 147篇 |
临床医学 | 952篇 |
内科学 | 2363篇 |
皮肤病学 | 164篇 |
神经病学 | 807篇 |
特种医学 | 447篇 |
外科学 | 1808篇 |
综合类 | 56篇 |
一般理论 | 5篇 |
预防医学 | 873篇 |
眼科学 | 203篇 |
药学 | 621篇 |
中国医学 | 15篇 |
肿瘤学 | 620篇 |
出版年
2023年 | 57篇 |
2022年 | 109篇 |
2021年 | 280篇 |
2020年 | 157篇 |
2019年 | 250篇 |
2018年 | 311篇 |
2017年 | 193篇 |
2016年 | 203篇 |
2015年 | 266篇 |
2014年 | 332篇 |
2013年 | 474篇 |
2012年 | 785篇 |
2011年 | 746篇 |
2010年 | 486篇 |
2009年 | 439篇 |
2008年 | 663篇 |
2007年 | 715篇 |
2006年 | 586篇 |
2005年 | 655篇 |
2004年 | 558篇 |
2003年 | 505篇 |
2002年 | 512篇 |
2001年 | 96篇 |
2000年 | 93篇 |
1999年 | 110篇 |
1998年 | 90篇 |
1997年 | 70篇 |
1996年 | 77篇 |
1995年 | 73篇 |
1994年 | 58篇 |
1993年 | 40篇 |
1992年 | 56篇 |
1991年 | 62篇 |
1990年 | 36篇 |
1989年 | 44篇 |
1988年 | 38篇 |
1987年 | 35篇 |
1986年 | 23篇 |
1985年 | 36篇 |
1984年 | 28篇 |
1982年 | 23篇 |
1981年 | 15篇 |
1980年 | 11篇 |
1979年 | 22篇 |
1978年 | 11篇 |
1973年 | 12篇 |
1971年 | 12篇 |
1970年 | 13篇 |
1969年 | 14篇 |
1968年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
61.
Camille Granger Paul Guedeney Camille Arnaud Soulef Guendouz Claire Cimadevilla Mathieu Kerneis Caroline Kerneis Michel Zeitouni Constance Verdonk Camille Legeai Guillaume Lebreton Pascal Leprince Eva Désiré Sabato Sorrentino Johanne Silvain Gilles Montalescot Fanny Hazan Shaida Varnous Richard Dorent 《Transplant international》2021,34(4):721-731
Available data on clinical presentation and mortality of coronavirus disease-2019 (COVID-19) in heart transplant (HT) recipients remain limited. We report a case series of laboratory-confirmed COVID-19 in 39 HT recipients from 3 French heart transplant centres (mean age 54.4 ± 14.8 years; 66.7% males). Hospital admission was required for 35 (89.7%) cases including 14/39 (35.9%) cases being admitted in intensive care unit. Immunosuppressive medications were reduced or discontinued in 74.4% of the patients. After a median follow-up of 54 (19–80) days, death and death or need for mechanical ventilation occurred in 25.6% and 33.3% of patients, respectively. Elevated C-reactive protein and lung involvement ≥50% on chest computed tomography (CT) at admission were associated with an increased risk of death or need for mechanical ventilation. Mortality rate from March to June in the entire 3-centre HT recipient cohort was 56% higher in 2020 compared to the time-matched 2019 cohort (2% vs. 1.28%, P = 0.15). In a meta-analysis including 4 studies, pre-existing diabetes mellitus (OR 3.60, 95% CI 1.43–9.06, I2 = 0%, P = 0.006) and chronic kidney disease stage III or higher (OR 3.79, 95% CI 1.39–10.31, I2 = 0%, P = 0.009) were associated with increased mortality. These findings highlight the aggressive clinical course of COVID-19 in HT recipients. 相似文献
62.
63.
64.
65.
66.
67.
68.
Benjamin Coiffard Philipp M. Lepper Eloi Prud’Homme Florence Daviet Nadim Cassir Heinrike Wilkens Sami Hraiech Frank Langer Pascal A. Thomas Martine Reynaud-Gaubert Robert Bals Hans-Joachim Schäfers Laurent Papazian Frederik Seiler 《American journal of transplantation》2021,21(4):1586-1596
It is unknown if solid organ transplant recipients are at higher risk for severe COVID-19. The management of a lung transplantation (LTx) program and the therapeutic strategies to adapt the immunosuppressive regimen and antiviral measures is a major issue in the COVID-19 era, but little is known about worldwide practice. We sent out to 180 LTx centers worldwide in June 2020 a survey with 63 questions, both regarding the management of a LTx program in the COVID-19 era and the therapeutic strategies to treat COVID-19 LTx recipients. We received a total of 78 responses from 15 countries. Among participants, 81% declared a reduction of the activity and 47% restricted LTx for urgent cases only. Sixteen centers observed deaths on waiting listed patients and eight centers performed LTx for COVID-19 disease. In 62% of the centers, COVID-19 was diagnosed in LTx recipients, most of them not severe cases. The most common immunosuppressive management included a decreased dose or pausing of the cell cycle inhibitors. Remdesivir, hydroxychloroquine, and azithromycin were the most proposed antiviral strategies. Most of the centers have been affected by the COVID-19 pandemic and proposed an active therapeutic strategy to treat LTx recipients with COVID-19. 相似文献
69.
Riekie Smit Elena Gubanova Joely Kaufman Marina Landau Beatriz Molina Bill Andriopoulos Pascal Maisonobe Inna Prygova Alessio Redaelli 《The Journal of clinical and aesthetic dermatology》2021,14(2):E69
BACKGROUND: AbobotulinumtoxinA (AboBoNT-A; Dysport®; Ipsen, Boulogne-Billancourt, France/Azzalure®; Galderma, Lausanne, Switzerland) is a botulinum neurotoxin type A approved for aesthetic use in the treatment of glabellar lines in adult patients under 65 years in Europe, the United States, and other countries. OBJECTIVE: We sought to analyze current literature on patient satisfaction with aboBoNT-A for upper facial aesthetic indications. METHODS: A systematic review of literature databases (PubMed/MEDLINE, Embase, the Cochrane Library, and Google Scholar) was performed to identify English-language publications reporting on patients with aesthetic indications (including glabellar lines and wrinkles) receiving aboBoNT-A, that assessed patient and/or physician satisfaction with treatment, with no restrictions on comparator studies. Structured data extraction was used to enable inter-study analysis. A post-hoc analysis was also performed to assess patient satisfaction by sex and age, using results from the noninterventional APPEAL study of patients’ satisfaction with aboBoNT-A for treating glabellar lines. RESULTS: Overall, 22 original research papers were identified. Patient satisfaction rates for aboBoNT-A treatment were significantly higher versus placebo from two weeks to between three and five months postinjection. At two to three weeks postinjection, patient satisfaction rates were 52% and 99% across studies. In studies with later time points, patient satisfaction rates were 85 to 87 percent at 5 months and between 25 and 100 percent at 6 months post-injection. Physician satisfaction was also high (97%–100%, across three treatments). No notable differences in patient satisfaction by sex or age were observed in the APPEAL study. CONCLUSION: High rates of patient satisfaction have been achieved with aboBoNT-A treatment for upper facial aesthetic indications. Despite the current recommended interval of ≥12 weeks, satisfaction with the aesthetic results of aboBoNT-A therapy is still evident up to 6 months post-injection in some patients. 相似文献
70.
Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease 总被引:2,自引:0,他引:2
Maerten P Geboes K De Hertogh G Shen C Cadot P Bullens DM Van Assche G Penninckx F Rutgeerts P Ceuppens JL 《Clinical immunology (Orlando, Fla.)》2004,112(3):239-246
4-1BB ligand (L) expressed on antigen presenting cells (APC) interacts with 4-1BB, expressed on activated T cells and this interaction costimulates T cells to secrete cytokines and to proliferate. We investigated whether 4-1BB/4-1BBL interactions might be involved in the pathogenesis of Crohn's disease (CD). In immunohistochemistry, we found 4-1BB expression on lamina propria (LP) cells in inflamed and to a lesser extend in non-inflamed gut tissue from CD patients. mRNA levels for 4-1BB were also elevated in intestinal CD tissue. In contrast, only few 4-1BB-expressing cells were found in inflamed tissue from ulcerative colitis (UC) patients and almost no positive cells were found in control intestinal tissue. 4-1BB expression was better sustained on in vitro activated lamina propria T cells from CD patients compared to controls. Finally, agonistic anti-4-1BB antibody enhanced interferon-gamma (IFN-gamma) production and proliferation of lamina propria T cells from CD patients. Taken together, our data suggest that 4-1BB/4-1BBL interactions contribute to the persistence of gut inflammation in CD. 相似文献